For many years, sorafenib has been the only approved systemic treatment for advanced hepatocellular carcinoma (HCC). For over a decade, randomized controlled trials exploring the efficacy of new drugs both in first- and second-line treatment have failed to prove any survival benefit. However, in the past few years, several advances have been made especially in pretreated patients; phase III trials of regorafenib, cabozantinib, and ramucirumab in patients with elevated α-fetoprotein have demonstrated efficacy in patients progressing after or intolerant to sorafenib. In addition, early phase I and II trials have shown promising results of immunotherapy alone or in combination with tyrosine-kinase inhibitors or monoclonal antibodies in the same setting of patients. In this review, we will discuss the evidence on second-line options for HCC, focusing on the latest results that are currently refining the treatment scenario.

Second-line treatment options in hepatocellular carcinoma

Zichi C.;Audisio M.;Di Maio M.
Last
2019-01-01

Abstract

For many years, sorafenib has been the only approved systemic treatment for advanced hepatocellular carcinoma (HCC). For over a decade, randomized controlled trials exploring the efficacy of new drugs both in first- and second-line treatment have failed to prove any survival benefit. However, in the past few years, several advances have been made especially in pretreated patients; phase III trials of regorafenib, cabozantinib, and ramucirumab in patients with elevated α-fetoprotein have demonstrated efficacy in patients progressing after or intolerant to sorafenib. In addition, early phase I and II trials have shown promising results of immunotherapy alone or in combination with tyrosine-kinase inhibitors or monoclonal antibodies in the same setting of patients. In this review, we will discuss the evidence on second-line options for HCC, focusing on the latest results that are currently refining the treatment scenario.
2019
8
1
13
https://www.drugsincontext.com/second-line-treatment-options-in-hepatocellular-carcinoma/
Cabozantinib; Hepatocellular carcinoma; Immunotherapy; Ramucirumab; Regorafenib; Second line; Treatment
Marino D.; Zichi C.; Audisio M.; Sperti E.; Di Maio M.
File in questo prodotto:
File Dimensione Formato  
dic.212577 Marino 2019.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 365.62 kB
Formato Adobe PDF
365.62 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1729979
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 27
  • ???jsp.display-item.citation.isi??? ND
social impact